- Home
- OBIO vs PRLD Comparison
OBIO vs PRLD Comparison
Compare OBIO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | PRLD |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 218.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OBIO | PRLD |
|---|---|---|
| Price | $4.51 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $14.25 | $4.67 |
| AVG Volume (30 Days) | 165.7K | ★ 203.9K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.13 | 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,482,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $12.43 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1169.22 | 73.43 |
| 52 Week Low | $2.20 | $0.72 |
| 52 Week High | $5.42 | $4.82 |
Technical Indicators
Market Signals| Indicator | OBIO | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 66.38 |
| Support Level | $4.02 | $1.02 |
| Resistance Level | $4.88 | N/A |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 59.49 | 75.62 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.